The Europe Tendonitis Treatment Market should witness market growth of 3.4% CAGR during the forecast period (2022-2028).
The fibers in the center of the tendon (above where it joins to the heel) are harmed in non-insertional achilles tendonitis. The fibers may start to deteriorate and form microscopic tears over time. Tendon edema and thickening may result from this. Younger, more active individuals, especially runners, are more prone to developing non-insertional tendinitis.
The majority of times, nonsurgical treatments for treating achilles tendonitis will be effective in reducing discomfort, though it might take a few months for symptoms to vanish. The discomfort may persist for more than three months, even with early therapy. Anti-inflammatory pain drugs, shoe wear modification, activity modification, and physical therapy exercises are the cornerstones of nonsurgical treatment.
Due to the region's enhanced healthcare infrastructure, innovative treatment facilities availability, and skilled experts, it is predicted that there would be a rising availability of tendonitis treatment in the near future. Another important factor that is projected to promote regional market expansion is the increased demand for advanced therapies in the Europe region.
The Germany market dominated the Europe Tendonitis Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $16,573.2 million by 2028. The UK market is anticipated to grow at a CAGR of 2.6% during (2022-2028). Additionally, The France market would exhibit a CAGR of 4.2% during (2022-2028).
Based on Type, the market is segmented into Therapy and Surgery. Based on Therapy Type, the market is segmented into Physical Therapy, Hot & Cold Therapy and Shockwave Therapy. Based on Condition, the market is segmented into Achilles Tendonitis, Jumper’s Knee, Tennis Elbow, Pitcher’s Elbow, Swimmer’s Shoulder and Golfer’s Elbow. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Merck & Co., Inc., Bayer AG, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Abbott Laboratories, Pfizer, Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., and Almatica Pharma, Inc.
The fibers in the center of the tendon (above where it joins to the heel) are harmed in non-insertional achilles tendonitis. The fibers may start to deteriorate and form microscopic tears over time. Tendon edema and thickening may result from this. Younger, more active individuals, especially runners, are more prone to developing non-insertional tendinitis.
The majority of times, nonsurgical treatments for treating achilles tendonitis will be effective in reducing discomfort, though it might take a few months for symptoms to vanish. The discomfort may persist for more than three months, even with early therapy. Anti-inflammatory pain drugs, shoe wear modification, activity modification, and physical therapy exercises are the cornerstones of nonsurgical treatment.
Due to the region's enhanced healthcare infrastructure, innovative treatment facilities availability, and skilled experts, it is predicted that there would be a rising availability of tendonitis treatment in the near future. Another important factor that is projected to promote regional market expansion is the increased demand for advanced therapies in the Europe region.
The Germany market dominated the Europe Tendonitis Treatment Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $16,573.2 million by 2028. The UK market is anticipated to grow at a CAGR of 2.6% during (2022-2028). Additionally, The France market would exhibit a CAGR of 4.2% during (2022-2028).
Based on Type, the market is segmented into Therapy and Surgery. Based on Therapy Type, the market is segmented into Physical Therapy, Hot & Cold Therapy and Shockwave Therapy. Based on Condition, the market is segmented into Achilles Tendonitis, Jumper’s Knee, Tennis Elbow, Pitcher’s Elbow, Swimmer’s Shoulder and Golfer’s Elbow. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stakeholders of the market. Key companies profiled in the report include Merck & Co., Inc., Bayer AG, AstraZeneca PLC, Boehringer Ingelheim International GmbH, Abbott Laboratories, Pfizer, Inc., GlaxoSmithKline PLC, Teva Pharmaceuticals Industries Ltd., and Almatica Pharma, Inc.
Scope of the Study
By Type
- Therapy
- Physical Therapy
- Hot & Cold Therapy
- Shockwave Therapy
- Surgery
By Condition
- Achilles Tendonitis
- Jumper’s Knee
- Tennis Elbow
- Pitcher’s Elbow
- Swimmer’s Shoulder
- Golfer’s Elbow
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Merck & Co., Inc.
- Bayer AG
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Abbott Laboratories
- Pfizer, Inc.
- GlaxoSmithKline PLC
- Teva Pharmaceuticals Industries Ltd.
- Almatica Pharma, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 4. Europe Tendonitis Treatment Market by Type
Chapter 5. Europe Tendonitis Treatment Market by Condition
Chapter 6. Europe Tendonitis Treatment Market by Country
Chapter 7. Company Profiles
Companies Mentioned
- Merck & Co., Inc.
- Bayer AG
- AstraZeneca PLC
- Boehringer Ingelheim International GmbH
- Abbott Laboratories
- Pfizer, Inc.
- GlaxoSmithKline PLC
- Teva Pharmaceuticals Industries Ltd.
- Almatica Pharma, Inc.
Methodology
LOADING...
